Table 2. . Pooled RAS prevalence estimates by patient characteristics.
| Variable | Subgroups | Pooled RAS prevalence estimate (%) | 95% CI | Number of data sources included in analysis |
|---|---|---|---|---|
| Overall RAS mutation prevalence | 43.6 | 38.8–48.5 | 12 | |
| Age (years) | 18–49 | 42.9 | 29.7–56.5 | 6 |
| 50–69 | 40.9 | 33.9–48.2 | 12 | |
| 18–69 | 42.1 | 36.8–47.5 | 12 | |
| ≥70 | 49.6 | 44.8–54.3 | 10 | |
| Gender | Female | 43.3 | 36.8–49.9 | 10 |
| Male | 43.8 | 39.0–48.6 | 12 | |
| Tissues from which DNA was isolated | Left colon | 42.7 | 37.8–47.6 | 9 |
| Right colon | 45.5 | 35.5–55.7 | 9 | |
| Rectum | 44.2 | 38.1–50.3 | 11 | |
| Site tumor sample was taken from | Primary | 43.3 | 36.9–49.9 | 9 |
| Metastatic | 51.3 | 43.0–59.5 | 3 | |
| Liver metastases† | Liver metastasis | 39.7 | 30.3–49.4 | 7 |
| No liver metastasis | 43.2 | 36.5–50.1 | 6 | |
| Metastatic development | Synchronous | 47.5 | 40.1–55.0 | 5 |
| Metachronous | 42.0 | 32.4–51.9 | 6 | |
| Tumor stage† | Stage I/II | 44.0 | 33.5–54.7 | 5 |
| Stage III | 40.4 | 32.4–48.6 | 5 | |
| Stage IV | 43.7 | 35.8–51.8 | 6 | |
| Line of treatment† | 1st line | 49.3 | 40.7–57.8 | 2 |
| 2nd line | 35.8 | 31.2–40.6 | 2 | |
| 3rd line or later | 39.2 | 33.4–45.1 | 2 | |
| Ratio of neoplastic cells as a percentage | <20% | 43.0 | 33.3–52.9 | 2 |
| ≥20% | 47.0 | 42.6–51.4 | 9 |
†Subgroups were based on patient status at the time the tumor sample was taken.